Sunday - May 11, 2025

LOGIN  |  REGISTER
Amneal Pharmaceuticals

Vor Bio to Participate in Upcoming Investor Conferences

April 18, 2023 | Last Trade: US$0.15 0.009 -5.62

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
Fireside Chat: Monday, April 24, 2023 at 9:30 am ET

H.C. Wainwright BioConnect Investor Conference
Fireside Chat: Tuesday, May 2, 2023 at 12:00 pm ET
Location: Nasdaq World Headquarters, New York, NY

The JMP Securities Life Sciences Conference
Fireside Chat: Tuesday, May 16, 2023 at 3:00 pm ET
Location: New York Hilton Midtown, New York, NY

A live webcast and archived replay of the fireside chats will be available on the investors section of our website, linked here: https://ir.vorbio.com/events-presentations/

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Investors & Media
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com

Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page